Cidara Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cidara Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to 2023.
  • Cidara Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$16M, a 75.5% decline year-over-year.
  • Cidara Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$121M, a 262% decline year-over-year.
  • Cidara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.9M, a 31.7% increase from 2022.
  • Cidara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$33.6M, a 20.9% increase from 2021.
  • Cidara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$42.5M, a 41.1% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.